Steele Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-4,321
Closed -$593K 104
2024
Q2
$593K Buy
4,321
+595
+16% +$79.4K 0.03% 91
2024
Q1
$511K Sell
3,726
-60
-2% -$8.19K 0.03% 98
2023
Q4
$514K Buy
+3,786
New +$462K 0.03% 91

Other funds holding IBB

Steele Capital Management's IBB Position: Q3 2024 in Review

Steele Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2024, closing a stake of 4,321 shares — an estimated $593K sold.

Steele Capital Management first reported a position in IBB in Q4 2023 and held it in 3 quarters. The position peaked at $593K in Q2 2024. 893 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

  • Steele Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2024 after selling out during the quarter.
  • Steele Capital Management sold 4,321 iShares Biotechnology ETF shares in Q3 2024, an estimated $593K.
  • Steele Capital Management first reported a position in iShares Biotechnology ETF in Q4 2023 and held it in 3 quarters.
  • Steele Capital Management's iShares Biotechnology ETF position peaked at $593K in Q2 2024.
  • 893 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Steele Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.